Ignite Creation Date:
2024-05-05 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00513968
Status:
COMPLETED
Last Update Posted:
2012-08-06
First Post:
2007-08-08
Brief Title:
Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine
Sponsor:
Genexine Inc
Organization:
Genexine Inc
Study Overview
Official Title:
A Single Center Randomized Open-label Dose Escalating Phase I Study to Evaluate the Safety of Intramuscularly Administered DNA Vaccine HB-110 Combined With Oral Antiviral Adefovir in Subjects With Chronic Hepatitis B Over a 48-week Period
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety and immunogenicity of a novel mixed plasmid DNA HB-110 combined with an antiviral agent Adefovir for the patients with chronic Hepatitis B infection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None